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We describe the actinomycete strain IMV-70 isolated from the soils of Kazakhstan, which produces potent antibiotics with high
levelsofantibacterialactivity.Aftertheresearchofitsmorphological,chemotaxonomic,andculturalcharacteristics,thestrainwith
potential to be developed further as a novel class of antibiotics with chemotherapeutics potential was identiﬁed as Streptomyces sp.
IMV-70. In the process of fermentation, the strain Streptomyces spp. IMV-70 produces the antibiotic no. 70, which was isolated
from the culture broth by extraction with organic solvents. Antibiotic compound no. 70 was puriﬁed and separated into individual
componentsbyHPLC,TLC,andcolumnchromatographymethods.Themaincomponentofthecompoundistheantibiotic70-A,
which was found to be identical to the peptolide etamycin A. Two other antibiotics 70-B and 70-C have never been described and
thereforearenewantibiotics.Thephysical-chemicalandbiologicalcharacteristicsofthesepreparationsweredescribedandfurther
researched. Determination of the optimal growth conditions to cultivate actinomycete-producer strain IMV-70 and development
of methods to isolate, purify, and accumulate preparations of the new antibiotic no. 70 enable us to research further the potential
of this new class of antibiotics.
1.Introduction
In the recent decades, pathogenic microorganisms with re-
sistance to common drugs have become increasingly wide-
spread; some examples include methicillin-resistant [1–4]
strains of Staphylococcus aureus (MRSA), vancomycin-resist-
ant strains of S. aureus (MRCNS or “methicillin-resistant
coagulase-negative staphylococci”), drug-resistant strains of
Streptococcus pneumoniae (DRSP), and vancomycin-inter-
mediate strains of S. aureus (VISA) [1–4]. MRSA have been
viewed as one of the leading nosocomial pathogens [5–7]. In
the last decade of the 20th century, there has been an unprec-
edented spread of MRSA on a global scale. According to
the data of the National Nosocomial Infections Surveillance
in the USA, in 1998, the proportion of MRSA in intensive
therapy wards reached 50%. At the same time the rate of
MRCNS occurrence rose to 70–80% without substantial var-
iation by region. These developments lead to signiﬁcant
complications in treating infections and pose a serious chal-
lengetomodernmedicine.Thesearchfornewnaturalantibi-
otics that overcome drug resistance of pathogenic microﬂora
isaviablesolutiontothisproblem.Suchresearchnecessitates
the systematic screening of producers of antibacterial antibi-
otics.
As a result of screening from Kazakhstan soils, six strains
of actinomycetes that produce antibiotics were isolated.
These strains produce antibiotics with a wide range of action
that is highly active against gram-positive microorganisms.
The new antibiotics were found to be highly active against
clinical strains of MRSA and MRCNS that exhibited multiple2 The Scientiﬁc World Journal
associatedresistancestothemaingroupsofantibioticswhich
included β-lactams, macrolides, aminoglycosides, ftorchi-
nolons, lincomycin, and chloramphenicol. Based on the ini-
tial study of its physical-chemical properties which includes
analysis of activity against a series of clinical agents during in
vitro e x p e r i m e n t sa sw e l la sa c u t et o x i c i t yi nm i c e ,t h en e w
antibiotic compound no. 70 was researched further for its
therapeutic potential.
The actinomycete strain IMV-70, which produces antibi-
otic no. 70 that showed high levels of antibacterial activity,
was isolated as a result of screening in the Institute of
Microbiology and Virology of Ministry of Education and
Science of Kazakhstan. This paper describes the research of
the producer strain IMV-70 and the highly active antibiotic
compoundno.70whichitproduces.Preliminaryresultshave
been published earlier [8].
2.MaterialandMethods
2.1. Strains and Media. The following bacterial strains were
used for testing antimicrobial activity: Comamonas terrigena
ATCC 8461, Bacillus subtilis ATCC 6633, Staphylococcus
aureus FDA 209 P, and clinical strains of methicillin-resist-
ant staphylococci spp., isolated from the materials of the
Central Clinical Hospital of the Medical Presidential Center
of Kazakhstan. Identiﬁcation of clinical strains and deter-
mination of their drug resistance were conducted on the
automatic bacteriological analyzer “mini API” (bioM´ erieux,
Marcy l’Etoile, France) with systems ID 32 STAPH and
ATB STAPH 5. Strains of Staphylococcus haemolyticus NMR
1626, NMR 1742, Staphylococcus epidermidis NMR 351,
NMR 793, Streptococcus agalactiae NMR 303, NMR 685,
and NMR 1002, and Enterococcus faecalis NMR 425, NMR
118, NMR 670, and NMR 733 were isolated from urine; S.
haemolyticusNMR1642 andNMR1656 fromprostatic ﬂuid;
S. agalactiae NMR 782 and Streptococcus oralis NMR 1565
from respiratory tract specimen; S. epidermidis NMR 813
from vaginal smear; S. epidermidis NMR 1694 and Entero-
coccus hirae NMR 459 from wound matter; S. haemolyticus
NMR 781 and Staphylococcus lugdunensis NMR 348 from
nasal smear; S. haemolyticus NMR 713 from eye mucus;
Streptococcus pneumoniae NMR 1150 from throat smear of
infected patients.
Bacterial species (staphylococci, streptococci, and ente-
rococci) for the tests were cultivated overnight at 37◦Co n
Columbia blood agar (AG Medical Company, India). The
antibiotic-producing bacterium, actinomycete strain IMV-
70, was isolated from a mud sample, collected in 2000
from the lake Kyzylkol in Southern Kazakhstan. The IMV-
70 strain was characterized based on the data from the
researchofitsmorphological,chemotaxonomic,andcultural
characteristics by means of standard methodologies [9–
13]. In order to study the morphology of its reproductive
structures, the strain was grown on oat agar at 28◦C. The
type of spore chains was determined on the 10th day of
growth. Study of morphological characteristics of the strain
IMV-70 was conducted using trinocular microscope Leica
DMLS with the digital video camera Leica DC 300F. The
strain was deposited in the collection of the Scientiﬁc Center
of the Russian Federation Research Institute for Genetics
and Selection of Industrial Microorganisms; the collection
number is VKPM As-1792.
2.2. Cultivation of the IMV-70 Strain and Extraction of Sec-
ondary Metabolites. In order to obtain spores, the IMV-70
strain was grown on mineral agar no. 1 and organic agar
no. 2 for 10 days at 28◦C as previously described [10]. The
composition of mineral agar no. 1 used was (g/L) soluble
starch 20.0; K2HPO4 0.5; MgSO4 0.5; NaCl 0.5; KNO3 1.0;
FeSO4 0.01; agar 20.0; pH 7.2–7.4. The composition of
organic agar no. 2 used was (%): Hottinger’s broth 3mL;
peptone 5.0; glucose 10.0; NaCl 5.0; agar 20.0; pH 7.0–7.2.
The vegetative inoculum was grown in 750mL Erlenmeyer
ﬂasks containing 100mL of medium and incubated at 28◦C
for 48 hours on a rotary shaker at 180–200rpm. The amount
of inoculum used for inoculation of the cultivation medium
equaled 1% (spore suspension = 109/mL). The composition
of cultivation medium used was (g/L) corn extract (weight
whendry)5.0;(NH)2SO4 3.5;NaCl5.0;CaCO3 5.0;insoluble
starch 15.0; glucose 10.0. The amount of inoculum for
inoculation of fermentation medium equaled 3% (vegetative
mycelium). The compositions of the fermentation media
used were (A) glucose 1.0; soy ﬂour 1.0; NaCl 0.5; CaCO3
0.25, and (B) yeast extract 5.0; glucose 20.0; peptone 10.0;
CaCO3 2.0; pH 7.3. Before sterilization, the pH value was
raised to between 7.4 and 7.6 using 0.1N NaOH.
Biosynthesis of the antibiotics was conducted in 750mL
Erlenmeyer ﬂasks containing 100mL of medium at 28◦Cf o r
96 hours on a rotary shaker. Antibiotic no. 70 was isolated
from culture broth of the producer IMV-70 by extraction
methods. The ﬂowchart for this extraction is shown in
Figure 1.
Analytical and preparative chromatography was carried
out by the TLC method on the DC-Alufolien Kieselgel 60
“Merck” (Germany) and Silufol (Czech Republic) plates
in a T1 solvent system, comprised of chloroform-benzene-
methanol(30:20:7)andT2:methanol-water(96:4).Puriﬁ-
cation and separation of the antibiotic compound into
individual components were also conducted by the method
of column chromatography on the Kieselgel 60 “Merck”
(Germany) silica gel. Suspension of silica gel in hexane was
loaded onto a column, and then the dry preparation mixed
with silica gel was added. The column was developed se-
quentially using diﬀerent organic solvents: hexane, chloro-
form, mixture of chloroform and methanol (90:10), and
methanol. Eluates from the column were analyzed by the
TLC method on the DC-Alufolien Kieselgel 60 “Merck”
(Germany)plates,withsubsequentdevelopmentofchromat-
ogramsbythemethodofbioautographywithBacillussubtilis
ATCC 6633 as the test organism. Active heterogeneous
fractions were united, dried in vacuo at 37◦C, and dissolved
in the minimal amount of ethanol. The antibiotic activity
was analyzed by the paper-disk agar diﬀusion method
(diameter of disks-6mm) with Bacillus subtilis ATCC 6633
(= RIA 445) and Staphylococcus aureus INA 00761 (MRSA)
as test organisms. HPLC analysis was conducted on liq-
uid chromatographer “Knauer” (Germany) with automated
data-processing system and spectrophotometric detectorThe Scientiﬁc World Journal 3
Filtration 
Mycelium Native  solution 
Extraction with acetone 
(2) Extraction with
      ethyl acetate 
Acetone extract  
Ethyl acetate extract 
Removal of acetone in vacuo 
(1) Removal of ethyl
       acetate in vacuo 
Aqueous residue 
Aqueous solution  Extraction with ethyl acetate   
(1) Repeated extraction
      with ethyl acetate
(2) Rinsing the extract with
      water (twice)
 
Ethyl acetate extract  
(1) Removal of ethyl acetate in
      vacuo
(2) Dissolution of residue  in EtOH
Alcohol concentrate M 
Ethyl acetate extract 
(1) Concentration in
       vacuo
(2) + excess hexane 
(3) Separation of residue
(4) Evaporation to dryness
       in vacuo
Crude powder 
Mother liquor and rinsing
water  
Discarded
Powdered antibiotic no. 70 
TLC and HPLC 
(2) Dissolution of residue
   in 0.1 N NaHCO3
(1) 1 N HCl to pH 4, 5
Culture broth, pH = 6.5
Figure 1:Flowchartforisolationofantibioticno.70.Antibioticno.70wasisolatedfromculturebrothoftheproducerIMV-70byextraction
methods. The ﬂowchart for the extraction that produces the powder preparation of compound no. 70 is shown in Figure 1. The antibiotic
no. 70 was isolated from culture broth by extraction with ethyl acetate, was subsequently puriﬁed from the inactive lipid fraction, and was
extracted from the concentrated solution with hexane.4 The Scientiﬁc World Journal
K = 2501; this was a stainless steel column (4 × 150mm),
ﬁlled with sorbent “Diaspher-110-C16, 5mcm” and “Chro-
masil A-100 C-18, 5mcm” (BioChimMac, Moscow). The
chromatographic conditions used were as follows: ﬂow
rate, 1mL/min; detection at wave lengths 260 and 300nm;
room temperature; loop, 20μL. Preparative isolation of
components of the antibiotic compound A-70 was carried
out through elution with a mixture of acetonitrile and water;
thecontentofacetonitrilewasgraduallyincreasedfrom10to
60%. The UV ranges were measured on spectrophotometer
Shimadzu 1601C (Japan). The mass ranges were measured
on Ultraﬂex 2 Tof/Tof by Bruker Daltonics (Germany) in the
positive ion mode, matrix 2,5 dihydroxybenzoic acid.
Analytical and semipreparative electrophoresis on paper
were conducted on V-shaped Durruma unit with the follow-
ing electrolytes: E1: 2 AcOH; pH 2.4; 550 V; 2hr. and E2:
85% HCOOH-AcOH-H2O (28:20:52); pH 1.1; 250 V; 2-
3hr. Bioautography was conducted by methods described in
the literature [14]. Bacillus subtilis ATCC 6633 (= RIA 445)
and Staphylococcus aureus FDA 209P (MSSA) and INA 00761
(MRSA) were used as test organisms.
2.3. Determination of the Antibacterial Activity by the Agar
Diﬀusion Method. Sterile disks (AG Medical Company,
India) containing 10μg/mL of crude powder of antibiotic
no. 70 in EtOH were placed on fresh plates of the Mueller-
Hinton agar seeded with bacterial suspensions at a cell
density of 5×105 CFU/mL of overnight cultures of the test
microorganisms. The Mueller-Hinton agar was poured into
the standard 80mm double dishes, at a volume of 20mL
per dish. The diameters of the zones of inhibition of growth
around the disks were measured after incubation periods of
18h at 37◦C.
The minimal inhibitory concentrations (MICs) were
determined by the broth dilution method by using the
Mueller-Hinton broth (MHB). The tubes containing 2mL of
serial twofold dilutions of each antimicrobial agent per well
wereinoculatedwith0.2mLofabacterialsuspensiontoyield
a cell density of 5 × 106 CFU/mL. MHB alone (tube with
2mL)hadnoeﬀect and was used as control. The tubes were
incubated for 48h, and visible growth was recorded after 18,
24, and 48h of incubation. The MIC recorded was the lowest
antibiotic concentration that completely prevented visible
growth after incubation at 37◦Cf o r1 8h .
3. Results
The producer strain IMV-70, related to the genus Strep-
tomyces, was isolated in the year 2000, at the Institute of
Microbiology and Virology MES RK. The optimal media
for biosynthesis of the antibiotic A-70 were found to be the
organic media with yeast and corn extracts, as well as soy,
pea, and oat ﬂour. The antibiotic was formed at the highest
rate in the medium with yeast extract and peptone on the
4th–7th day of fermentation and will be described in greater
detail below.
3.1. Producer Strain IMV-70. The producer strain IMV-
70 forms aerial mycelium with a diameter of hyphae of
approximately 0.3–0.6μM (data not shown). Spore chains
shaped like hooks, loops, and spirals were observed (RA,
retinaculum-apertum). Occasionally, long straight chains
were also observed (RF, rectus-ﬂexibilis). The strain IMV-
70 forms long cylindrical spore chains that contain more
than 10 spores per chain and have a smooth surface (data
not shown). Cultural characteristics were studied after two
weeks of cultivation. The strain preserves stable cultural
characteristics during cultivation when grown on diﬀerent
media, which included mineral agar, organic agar, sucrose-
nitrate agar, inorganic salts-starch agar (ISP No. 4), glucose-
asparagine agar (ISP No. 5), oatmeal agar (ISP No. 3),
tyrosine agar (ISP No. 7), and peptone-yeast agar with iron
(ISP No. 6). On the researched media, the strain forms a
soluble pigment in the color range from light brown to
brown. Melanin was not formed on the media ISP No. 6 and
7.Physiologicalanalysesofstraincharacteristicsrevealedthat
strain IMV-70 utilizes the majority of carbon sources. The
strain has tyrosinase, amylolytic and weak gelatinase activity,
and peptonized milk. The taxonomic study identiﬁed the
strain as Streptomyces sp. IMV-70. The tests of fermenta-
tion conditions indicated that the media components had
signiﬁcant inﬂuence on the formation of this antibiotic
component. The optimal media for biosynthesis of the
antibiotic no. 70 were the organic media with yeast and
corn extract, as well as with soy, pea, and oat ﬂour. The
maximum antibiotic activity of culture broth develops on
the 4th–7th day of fermentation. Addition of CoCl2 and
ZnSO4 intheconcentrationof0.0005g/Ltothemediasignif-
icantly stimulates antibiotic formation. The antibiotic no.
70 was isolated from culture broth by extraction with ethyl
acetate and was subsequently puriﬁed from the inactive lipid
fraction and extracted from the concentrated solution with
hexane (Figure 1).
3.2. Antimicrobial Activity. Antibiotic no. 70 was found to
be highly active against the following test organisms: Coma-
monas terrigena ATCC 8461, Bacillus subtilis ATCC 6633,
and Staphylococcus aureus FDA 209 P. Minimum inhibitory
concentration is within the range of 0.25–0.05μg/mL (Table
1(a)). The agar diﬀusion method was used for determining
the activity of antibiotic no. 70 against various clinical
strains of staphylococci, streptococci, and enterococci (Table
1(b)). The antibiotic no. 70 highest activity was against
staphylococci and streptococci, whereas its activity against
enterococci was weaker.
The highest activity of antibiotic no. 70 was recorded
against clinical cocci strains: MRSA and MRCNS with differ-
ent types of drug resistance (data not shown). The MIC for
the collected group of clinical pathogen was within the range
of0.1–0.025μg/mL.Tosummarizetheantimicrobialactivity,
we found in this study that the antibiotic no. 70 was active
against gram-positive and gram-negative test organisms test-
ed: Bacillus anthracis (I Tsenkovsky’s vaccine), Bacillus an-
thracoides, Staphylococcus aureus 209 P, Pasteurella multocida,
Mycobacterium citreum,a n dKlebsiella pneumoniae 444.T h e
minimal inhibiting concentration of the powdered prepara-
tions of the antibiotic no. 70 with diﬀerent maximum values
of absorption in UV light was as follows: the preparationThe Scientiﬁc World Journal 5
Table 1: (a) Antimicrobial activity of antibiotic no. 70. (b) Antimi-
crobial activity of antibiotic no. 70 against clinical microorganisms.
(a)
Test organisms Minimum inhibitory
concentration, μg/mL
Comamonas terrigena ATCC 8461 0.1
Bacillus subtilis ATCC 6633 0.25
Staphylococcus aureus FDA 209 P 0.05
(b)
Microorganisms Inhibition zone size (mm)
S. haemolyticus NMR 713 24
S. haemolyticus NMR 1626 22
S. haemolyticus NMR 1642 22
S. haemolyticus NMR 1742 24
S. epidermidis NMR 1656 22
S. epidermidis NMR 1694 21
S. epidermidis NMR 351 23
S. epidermidis NMR 793 22
S. epidermidis NMR 813 23
S. haemolyticus NMR 781 20
S. lugdunensis NMR 348 24
Str. agalactiae NMR 303 22
Str. agalactiae NMR 685 22
Str. agalactiae NMR 782 22
Str. agalactiae NMR 1002 25
Str. oralis NMR 1565 26
Str. pneumoniae NMR 1150 24
Enterococcus hirae NMR 459 19
Enterococcus faecalis NMR 425 16
Enterococcus faecalis NMR 118 16
Enterococcus faecalis NMR 670 17
Enterococcus faecalis NMR 733 16
with λmax 260nm was 0.5–0.05μg/mL while the preparation
with λmax 300nm was 0.25–0.05μg/mL. The antibiotic no.
70 was also found to be active against virulent cultures of
Listeria monocytogenes, Erysipelothrix rhusiopathiae,a n dY.
pestis. Its activity is especially high against clinical cocci
strains: staphylococci, streptococci, micrococci, enterococci,
and aerococci with diﬀerent types of drug resistance. Activity
of the antibiotic no. 70 was studied against clinical MRS-
strains with resistance to macrolides (erythromycin), amino-
glycosides (gentamicin), lincosamides (lyncomycin), and
ftorchinolons (ciproﬂoxacin, oﬂoxacin, and levoﬂoxacin). In
the tests with staphylococci strains, the minimal inhibiting
concentration of the powdered preparation A-70 with λmax
260nm equaled 0.4–0.1μg/mL; the preparation with λmax
300nm required 0.1–0.025μg/mL.
According to the Government Standard 12.1.007-76
(requirements for detergents and domestic chemical prod-
ucts; Principles on Good Laboratory Practice implemented
as National Standard in 2010), the powdered preparations
of the antibiotic no. 70 were classiﬁed as belonging to the
4th class of toxicity:slightly toxic substances (for white mice
LD50 at inoculation into stomach >5000mg/kg) (data not
shown). Toxic, embryotoxic, and local irritating action of
the antibiotic no. 70 was not discovered. The experiments
with MRSA-induced sepsis in white mice determined that
antibiotic no. 70 had distinctive medical eﬀect for 90% of
the infected mice and increased their lifespan (data not
shown). During the autopsy, only isolated abscesses were
discovered in the internal organs of the mice, treated with
the preparation.
3.3. Chemical Identiﬁcation. According to the data of elec-
trophoresis on paper, the antibiotic no. 70 was electroneu-
tral. TLC on plates DC-Alufolien Kieselgel 60 “Merck”
(Germany) with several solvent systems showed that the
antibiotic no. 70 was a compound containing at least 4
biologically active components. In the system chloroform-
benzene-methanol (30:20:7), the main component A has
Rf = 0.65; the component B had an Rf = 0.35, while the
components C and D were minor. Conditions of HPLC
analysis on liquid chromatographer “Knauer” (Germany)
weredevelopedforamorepreciseseparationoftheantibiotic
compound no. 70 and determination of its components’
ratio (Figure 2(a)). Figure 2(a) shows the chromatogram of
separation of the antibiotic compound no. 70.
As shown in Figure 2(a), the main component of
the compound is the component with retention time of
17.85min. This component constitutes 72–74% of the com-
pound and was labeled as the component 70-A. The com-
ponent 70-B (retention time = 19.41min) constitutes ap-
proximately 4% of total components. The components C
and D are minor and together add up to less than 1%.
The conditions for preparative isolation of individual com-
ponents on chromatographer “Knauer” (Germany) were
developed.Thesalt-freesystemacetonitrile-wateringradient
elutionmodefrom10to60%ofacetonitrilewithdetectionat
300nm met these optimal conditions. By HPLC method the
chromatographically pure sample of the main component
70-A was isolated (Figure 2(b)). Table 2 summarizes certain
physical-chemical characteristics of antibiotic 70-A.
The compiled data enabled the identiﬁcation of 70-A
through BNPD, a method developed by B´ eahdy (Hungary)
[15]; the antibiotic compound no. 70-A was determined to
exhibit characteristics closest to the antibiotic etamycin A
[16–18], which belongs to the group of antibiotics pep-
tolides-heteropeptidolactones [19, 20]. This group also in-
cludes other antibiotics such as etamycin, pristinamycin,
and griseoviridin, as well as other antibiotics with high an-
tibacterial activity and synergistic eﬀect [20]. “Synercid,”
the compound of semisynthetic antibiotics of this group,
which includes quinupristin and dalfopristin, is highly active
against a number of vancomycin-resistant bacteria and is
currently being used in medicine [21, 22].
The direct comparison and the component 70-A and a
sample of etamycin A by methods of TLC, HPLC, UV, MS-
spectrometry showed that these compounds are identical.
Thus, the antibiotic no. 70-A was identiﬁed as etamycin6 The Scientiﬁc World Journal
Table 2: Physical-chemical characteristics of antibiotic 70-A.
UV range (EtOH), λmax, nm (E1%1cm) 300 (84)
UV range (H2O), λmax, nm (E1%1cm) 340 (80)
HPLC on “Knauer” (Germany), column 4 × 150mm ﬁlled with sorbent
“Chromasil A-100 C-18, 5mcm” (BioChimMac, Moscow), retention time, min. 17.85
Purity of the preparation according to HPLC data 95%
Molecular mass, method MS MALDI-TOF m/z 879 (M+H)+, 901 (M+Na)+, 917 (M+K)+
TLC, Kieselgel 60 (Merck) plates
System: chloroform-benzene-methanol (30:20:7) 0.64
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Figure 2: (a) HPLC of antibiotic compound no. 70. HPLC analysis was conducted on liquid chromatographer “Knauer” (Germany) with
automated data processing system and spectrophotometric detector K = 2501. The chromatographic conditions used were as follows:
ﬂow rate, 1mL/min; detection at wave length 260 and 300nm; room temperature; loop, 20μL. Preparative isolation of components of the
antibiotic compound A-70 was carried out through elution with a mixture of acetonitrile and water; the content of acetonitrile was gradually
increased from 10 to 60%. The main component of the compound is the component with a retention time of 17.85min. This component
constitutes 72–74% of the compound, and was labeled as the component 70-A. Figure 2(a) shows the chromatogram of separation of the
antibiotic compound no. 70. The component 70-B (retention time = 19.41min) constitutes approximately 4% of total components. The
components C and D are minor and together add up to less than 1%. The conditions for preparative isolation of individual components on
chromatographer “Knauer” (Germany) were developed. The salt-free system acetonitrile-water in gradient elution mode from 10 to 60% of
acetonitrile with detection at 300nm met these optimal conditions. (b) HPLC of the extracted and puriﬁed main component 70-A. Conditions
ofHPLCanalysisonliquidchromatographer“Knauer”(Germany)weredevelopedforamorepreciseseparationoftheantibioticcompound
no. 70 and determination of its components’ ratio. By HPLC method, the chromatographically pure sample of the main component 70-A
w a si s o l a t e da ss h o w ni nFigure 2(b).
A with the same chemical structure represented (data not
shown). As described above and previously [8, 14], fermen-
tation conditions signiﬁcantly inﬂuence antibiotic formation
and component composition of the antibiotic compounds of
antibiotic no. 70. The most eﬃcient preparations are formed
on medium B with yeast extract. The antibiotic compounds
with a higher ratio of minor components and lower ratio of
the main component A are formed on medium A with soy
ﬂour, in contrast to the medium containing yeast extract,
whereby the component A makes up to 74% of the com-
pound (Figure 3).
The new antibiotic components 70-C and 70-D were
isolated by HPLC on “Knauer” (Germany), column 4 ×
150mm ﬁlled with sorbent “Chromasil A-100 C-18, 5mcm”
(BioChimMac,Moscow).Someoftheirassociatedcharacter-
istics are summarized in Table 3.
The components 70-C and 70-D have no analogues in
BNPD, and quite possibly, have never been described before.
The research of antibiotics 70-C and 70-D, which are novel
components, is in progress. The ﬁndings of this study indi-
cated that the antibiotic no. 70 has a signiﬁcant potential
application in medicine.The Scientiﬁc World Journal 7
Table 3: Characteristics of certain minor components of antibiotic no. 70.
Components of antibiotic no. 70 UV-range, λmax, nm,
(C2H5OH) Molecular mass, m/z, MS HPLC, “Knauer”
Components of antibiotic no. 70 MALDI-TOF method Retention time,
min.
Purity of the
components, %
Component 70-C 210; 260.2; 328 (bend) 917 17.53 97.06
Component 70-D 197; 248; 302 622 14.11 93.0
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Figure 3: Chromatogram of antibiotic compound no. 70, formed in
medium A with soy ﬂour. The antibiotic compounds with a higher
ratio of minor components and lower ratio of the main component
A are formed on medium A with soy ﬂour, in contrast to the
medium containing yeast extract, whereby component A makes up
to 74% of total compounds (as shown in Figure 2). Figure 3 shows
the chromatogram of the main component of compound no. 70
formed in medium A with soy ﬂour.
4. Discussions
One of the goals of this study was to determine the taxonomy
of actinomycetes strain IMV-70, the producer of antibiotic
compound no. 70. Preliminary screening and analysis by
PCR method identiﬁed strain IMV-70 to be closely related
to Streptomyces niveoruber and Streptomyces thermodiastati-
cus, but diﬀers from them by cultural and morphological
properties (data not shown). The optimal conditions for
media and cultivation of IMV-70 were determined followed
by development of methods for isolating and purifying the
antibiotics no. 70. The latter study goal was performed to
determine optimal methodologies and conditions which can
be applied and adapted for large-scale preparations of the
new antibiotic no. 70 and its puriﬁed components. The
optimal media for biosynthesis of the antibiotic no. 70 were
found to be the organic media with yeast and corn extracts,
as well as soy, pea, and oat ﬂour. The antibiotic was formed
at the highest rate in the medium with yeast extract and
peptone on the 4th–7th day of fermentation. We found in
this study that the antibiotic no. 70 was active against
gram-positive and gram-negative test organisms tested and
was found to be active against virulent cultures of Listeria
monocytogenes, Erysipelothrix rhusiopathiae,a n dY. pestis.
The overall antimicrobial activity was especially high against
clinical cocci strains: staphylococci, streptococci, micrococci,
enterococci, and aerococci with diﬀerent types of drug
resistance.
Research of the physical-chemical properties of the
antibiotic compound shows that the antibiotic 70-A belongs
to the heteropeptidolactone group, along with etamycin,
pristinamycin, griseoviridin, and other antibiotics with high
antibacterialandsynergisticactivity.Theantimicrobialactiv-
itiesofantibiotic70-Adescribedinthisstudywereconsistent
with reported anti-MRSA activities of naturally produced
etamycin-isolated marine-derived actinomycetes [23].
In this study, we were able to determine the optimal
growth conditions to cultivate actinomycetes producerstrain
IMV-70 and developed methods to isolate, purify, and
accumulate preparations of the new antibiotic no. 70. The
continuing research of the producer strain IMV-70 and its
antibiotic compounds 70-A, 70-B and 70-C will enable us to
discover the new nontoxic antibiotics, highly eﬃcient against
the clinical strains of MRSA and other dangerous infections.
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